The Need for Quantitative Imaging in Ocology在肿瘤的定量成像的需要.pptVIP

The Need for Quantitative Imaging in Ocology在肿瘤的定量成像的需要.ppt

  1. 1、有哪些信誉好的足球投注网站(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
The Need for Quantitative Imaging in Ocology在肿瘤的定量成像的需要

The Need for Quantitative Imaging in Oncology Richard L. Schilsky, M.D. Professor of Medicine, Associate Dean for Clinical Research, University of Chicago Chairman, Cancer and Leukemia Group B The Role of Imaging in Oncology Detection Staging (assess prognosis) Treatment planning Assess response/progression (assess benefit) Monitor recurrence The Role of Imaging in Oncology Is a tumor present? Where is it? How big is it? How deep is it? What is it near? Is it growing/shrinking/spreading? Clinical Practice vs. Clinical Research Mostly a matter of precision Practice setting: information that impacts clinical management of an individual, e.g., when to start/change/stop treatment; assess extent of disease and cause of symptoms Research setting: information that assesses an intervention in a population, e.g., precise staging; accurate tumor dimensions; assessment of response/progression Clinical Benefit Improved survival compared to no treatment or to a known effective therapy Non-inferiority to a known effective therapy Improvement in TTP compared to known effective treatment coupled with symptomatic improvement Activity vs. Benefit Don’t confuse activity with benefit Activity is the effect on a surrogate or clinical endpoint of administering the drug Efficacy is the overall benefit (adjusted for risk) of prescribing the drug (for a specific indication) Activity is necessary – but not sufficient – for efficacy Survival Unambiguous endpoint that is not subject to investigator interpretation or bias from unblinded studies Assessed easily, frequently No tumor measurements required!! Response Rate Treatment is “entirely” responsible for tumor reduction; unlikely due to natural history Endpoint reached quickly Response criteria arbitrary %CR and duration of response important Classical endpoint to screen for activity; accepted surrogate for clinical benefit Response Criteria WHO: PR is 50% decrease in the sum of the product of the perpendicular diameters of measurabl

您可能关注的文档

文档评论(0)

erterye + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档